This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Establishment Labs Holdings (ESTA) and Gilead Sciences (GILD)

Tipranks - Fri Jun 12, 10:04PM CDT

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Establishment Labs Holdings (ESTA) and Gilead Sciences (GILD) with bullish sentiments.

Introducing TipRanks MCP for Agents

Establishment Labs Holdings (ESTA)

TD Cowen analyst Josh Jennings reiterated a Buy rating on Establishment Labs Holdings yesterday and set a price target of $95.00. The company’s shares closed last Thursday at $85.11.

According to TipRanks.com, Jennings is a 3-star analyst with an average return of 2.1% and a 45.8% success rate. Jennings covers the Healthcare sector, focusing on stocks such as Anteris Technologies Global Corp., Orchestra BioMed Holdings, and Baxter International. ;'>

Currently, the analyst consensus on Establishment Labs Holdings is a Strong Buy with an average price target of $89.50.

See the top stocks recommended by analysts >>

Gilead Sciences (GILD)

Wells Fargo analyst Mohit Bansal maintained a Buy rating on Gilead Sciences yesterday and set a price target of $165.00. The company’s shares closed last Thursday at $125.87.

According to TipRanks.com, Bansal is a 5-star analyst with an average return of 9.2% and a 56.8% success rate. Bansal covers the Healthcare sector, focusing on stocks such as Mineralys Therapeutics, Inc., BioMarin Pharmaceutical, and Vertex Pharmaceuticals. ;'>

Currently, the analyst consensus on Gilead Sciences is a Strong Buy with an average price target of $160.11, a 31.5% upside from current levels. In a report issued on June 2, Bank of America Securities also maintained a Buy rating on the stock with a $162.00 price target.

Read More on ESTA:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.